London, November 6 (IANS) While over 24 lakh pregnant women in India were colonised with Group B Streptococcus (GBS) bacteria in 2015, the bacteria accounded for 13,000 infant deaths — the highest in the world — a study involving more than 100 researchers and 11 research papers globally claimed on Monday.
GBS is a major, yet preventable, type of bacterial infection that can be found in a pregnant woman’s vagina or rectum and is responsible for maternal and infant ill-health globally.
The researchers conservatively estimate that out of 410,000 GBS cases every year, there will be at least 147,000 still-births and infant deaths globally¹.
Emphasising the need for a maternal GBS vaccine, the team, led by London School of Hygiene & Tropical Medicine, revealed that Nigeria with 8,000 infant GBS-related deaths ranked second, followed by Ethiopia (4,000), Democratic Republic of the Congo (4,000) and Pakistan (3,000).
When it comes to infant GBS disease cases, India again topped with 31,000 infant disease cases. China was second with 25,000 cases, followed by Nigeria (22,000), Democratic Republic of the Congo (16,000) and Egypt (14,000).
“Antibiotics currently prevent an estimated 29,000 cases of early-onset GBS disease per year, almost all in high-income settings. However, this approach may be difficult in low-income settings where many births take place at home, and laboratory capacity for screening for GBS is limited,” said Joy Lawn, Professor at London School of Hygiene & Tropical Medicine.
The GBS bacteria was found to be present in an average of 18 per cent of pregnant women worldwide carrying the bacteria — ranging from 11 per cent in eastern Asia to 35 per cent in the Caribbean — totalling 21.7 million in 195 countries.
The top five countries by numbers (to nearest 100) of pregnant women colonised were: India (2,466,500) China (1,934,900), Nigeria (1,060,000), the US (942,800) and Indonesia (799,100).
“In addition, giving antibiotics to 21.7 million women may contribute to antimicrobial resistance — a major global health crisis,” Lawn added.
Despite being home to only 13 per cent of the world’s population, Africa had the highest burden, with 54 per cent of estimated cases and 65 per cent of still-births and infant deaths, said the study published in the journal Clinical Infectious Diseases.
The study urged for the development of an effective GBS vaccine, saying that immunising expectant mothers is a potentially ground-breaking approach that could dramatically reduce the number of maternal and child deaths.
According to the researchers, a maternal GBS vaccine, which is just 80 per cent effective and is able to reach at least 90 per cent of women, could potentially prevent 231,000 infant and maternal GBS cases globally.
“Even if antibiotics were given to all pregnant women identified through screening strategies, they target mainly early-onset GBS disease in newborns, not GBS disease in pregnant women, GBS disease before delivery causing stillbirth, or GBS disease in infants more than a couple of days old”, explained Anna Seale, Associate Professor at the varsity.
Although several vaccines to prevent GBS are in development, none is currently available. Current GBS prevention focuses on giving antibiotics to women in labour, aiming to reduce disease in infants at delivery.
Only “a maternal GBS vaccine could prevent many more cases and deaths worldwide”, Seale added.